Healthy Clinical Trial
Official title:
Measurement of Exhaled Lower Respiratory Carbon Monoxide and Correlation With Previous Measures of Red Cell Lifespan
Hemoglobin A1C (HbA1c) is the cornerstone of blood sugar monitoring. As HbA1c is formed by the covalent reaction of glucose with hemoglobin throughout the lifespan of the red blood cell (RBC), it is used as a surrogate marker for integrated mean blood glucose over time. The HbA1c value therefore is dependent on the average amount of time the RBC spends in the circulation (mean RBC age or MRBC). However, our previous studies measuring red cell lifespan using either an age cohort label (ex vivo labeling with biotin) or a population label (stable isotope) have demonstrated, contrary to established dogma, that the MRBC varies substantially among individuals and is sufficiently variable to affect HA1c interpretation in a significant percentage of individuals with diabetes. Although the stable isotope method is suitable for clinical studies, it has limited potential for application to large population of subjects. A potential alternative to the stable isotope approach that could be applied routinely to the average patient in the clinic is measurement of exhaled carbon monoxide (eCO) concentration, a reflection of RBC heme turnover. In general, the primary advantage of applying exhaled breath analyses to human clinical diagnostics and therapeutic monitoring is that this technique is noninvasive, safe, simple, and provides near-real time measurements. The purpose of this observational study is to optimize the collection of eCO in a normal control population followed by measurement in a cohort of subjects previously assessed by either the SI or biotin methods for comparison.
Recently Investigators have demonstrated that RBC lifespan has substantial inter-individual
variation even in people without diabetes or obvious hematologic diseases affecting RBC
lifespan (5,6). Investigators combined Endocrinology-Hematology research group has taken a
leading role in applying state-of-the-art methods for RBC survival measurement.The published
articles articles are now cited when investigators refer to the state of the art
understanding of true RBC lifespan (7). Using a biotin labeling method that involves ex vivo
labeling of cells with biotin and then re-infusion of those cells, Investigators were able to
demonstrate that RBC lifespan is sufficiently heterogeneous even in the hematologically
normal population with normal reticulocyte count to significantly affect HbA1c interpretation
(5). Recognizing the limitations of the safe but relatively invasive biotin technique,
Investigators more recently developed a stable isotope (SI) in which RBC heme is labeled with
orally administered 15N-glycine (6). This is a benign and noninvasive technique and expands
the scope of RBC lifespan studies to sizable epidemiologic and physiologic studies, a number
of which investigators are initiating and planning.
However, the feasibility of making the findings translatable to widespread patient care has
been perceived as a limitation to the merit of answering these scientific questions. The SI
approach still requires multiple blood measurements over months (6). This proposed project is
designed to test the feasibility of a method to satisfy the unmet clinical need for measuring
RBC survival easily, noninvasively, and inexpensively. The goal is to access most individuals
with or at risk for diagnosis of diabetes in or near most doctors' offices. Over the next
year Investigators intend to determine whether exhaled alveolar carbon monoxide (eCO), a
measure of heme breakdown and hence of RBC turnover, can be used in this manner to provide a
single point measure of RBC lifespan. Interestingly, heme metabolism is the only known
endogenous source of carbon monoxide in people (8) and there are recent studies by others
suggesting its potential for measuring RBC lifespan (9,10) Now that technology has advanced
to measure CO with sufficient sensitivity and cost, investigators will explore the use of
instrumentation at the same time investigators expand their studies using the SI approach.
The results from this method will be compared with a previous small population of subjects
that had lifespan measured by biotin and/or SI technique.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |